MultiplexDX joined the global oncology community at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, one of the world’s largest and most influential oncology conferences. ASCO attracts over 40,000 professionals annually, providing a platform to showcase pioneering research and discuss advancements shaping the future of cancer care.
At this prestigious event, we presented a poster on our novel mFISHseq method. This advanced technique demonstrated strong concordance with immunohistochemistry (IHC) results. By integrating laser capture microdissection (LCM), the method isolates tumor-enriched samples free from contamination by non-tumor elements, enabling precise and spatially resolved analysis of tumor heterogeneity. This breakthrough addresses a long-standing challenge in accurately diagnosing and classifying breast cancer subtypes, offering a significant advancement in personalized cancer treatment strategies.
We are thankful for the opportunity to share our research and, in turn, receive excellent response and feedback.
For more information, read full abstract.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter